Next-gen malaria vaccine overcomes major hurdle
Original story from WEHI (Parkville, Australia).
New research co-led by WEHI (Parkville, Australia) and Burnet Institute (Melbourne, Australia) has uncovered how the human immune system fights Plasmodium vivax, paving the way for the first effective vaccine against the most widespread form of malaria.
The study provides critical evidence of how protective immunity to P. vivax works, identifying specific targets on the parasite and explaining how antibodies function to prevent and clear infection.
The findings, co-led by Rhea Longley and Ivo Mueller, are published in Immunity.
Addressing an urgent, unmet need
Longley, a WEHI Laboratory Head, said global malaria research and vaccine investment has overwhelmingly focused on Plasmodium falciparum, leaving major knowledge gaps for P. vivax.
“Unlike P. falciparum, P. vivax has unique biological features including a dormant liver stage that causes relapses, making it more difficult to eliminate,” she explained. “Strategies that work for one species do not translate to the other.”
Burnet Senior Research Fellow Herber Opi added that as a result, global efforts to control malaria have stalled despite decades of progress.
“While two malaria vaccines have been rolled out in parts of Africa, both target Plasmodium falciparum and offer no protection against P. vivax, which dominates in Asia and the Pacific.”
A major obstacle to developing a P. vivax vaccine has been limited understanding of what protective immunity actually looks like.
Uncovering a promising target for malaria therapeutics
A family of proteins in a malaria-causing parasite could be a promising new drug target, with the potential to overcome the growing issue of drug resistance.
Shaping vaccine design
James Beeson, Head of Malaria Immunity and Vaccines at Burnet, said the findings provide critical evidence to guide vaccine design.
“These exciting findings open new avenues for developing P. vivax vaccines to combat the malaria burden globally and support a path to elimination,” Beeson commented.
Using blood samples from children in Papua New Guinea – a region heavily affected by P. vivax –researchers examined how antibodies interact with the immune system to prevent disease.
The findings show that protection from P. vivax is not driven by the presence of antibodies, but by how those antibodies function and which parasite proteins they target.
Researchers identified antibody responses that recruit immune cells and activate immune pathways to attack the parasite. The immune system response was significantly stronger when it targeted multiple proteins at once.
Targeting the right combination of proteins was crucial and could reduce malaria risk by more than 75% – a finding that provides a clear strategy for future vaccine development.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.